Insider purchase at Epizyme (EPZM) comes in face of Selling Trend of Last 90 Days

Monday, September 18, 2017 10:15 PM ET

Insider purchase at Epizyme (EPZM) comes in face of Selling Trend of Last 90 Days

One insider — David M Mott, Director — today, purchased 200,000 shares of Epizyme having a market value of approximately $3,050,000, as revealed in a form 4 document filed with the SEC. There was one insider buy/sell transaction in the past 90 days prior to this transaction which resulted in the sale of 3,024 shares. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 196,976 shares and have averaged 101,512 shares per transaction over this time period.

During the last 90 days, the number of insider buy/sell trades at Epizyme is above the 266-company peer group average. Bio Therapeutic Drugs peer group saw 303 buy/sell trades during this period for an average of 1.1 transactions per company. The number of shares per buy/sell trade for Epizyme insiders was also higher. Within the peer group there were 8,183,694 shares purchased and 16,484,463 shares sold with company insiders selling 27,395 shares on average.

The data used in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.